Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects,Coris 2008

Abstract

Background

The aim of this study was to estimate the persistence of the most commonly used first-line combined antiretroviral regimens (cART) in HIV-infected adults in the CoRIS cohort.

Methods

CoRIS is an open prospective multicentre cohort of HIV-infected adults naive to cART at entry. Patients enrolled between January 2008 and June 2010 were included. The main outcome was treatment persistence, defined as time from cART initiation to first treatment change (TC). Cox models taking into account competing risks to estimate sub-hazard ratios (sHR) were performed.

Results

Of 1,512 patients, 919 (60.8%) initiated cART with the backbone tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) plus efavirenz (EFV), 252 (16.7%) plus lopinavir/ritonavir (LPV/r), 129 (8.5%) plus atazanavir/ritonavir (ATV/r), 110 (7.3%) plus darunavir/ritonavir (DRV/r) and 102 (6.7%) plus nevirapine (NVP). Among 414 patients who switched therapy, reason for switching was available for 393. The most frequent reasons were toxicity (40%), simplification (14%) and treatment failure/resistance (13%). In multivariate analyses, there were significant differences in the risk of TC according to initial cART regimen (P<0.001). Initiating TDF plus FTC with NVP (sHR 1.94, 95% CI 1.38, 2.72) or LPV/r (sHR 1.89, 95% CI 1.45, 2.47) was associated with higher risk of TC than initiating with TDF plus FTC plus EFV. No differences in TC were found between initiating EFV versus ATV/r (sHR 1.29, 95% CI 0.89, 1.86) or DRV/r (sHR 0.98, 95% CI 0.59, 1.65) with TDF plus FTC as backbone.

Conclusions

Switching from initial cART regimens is frequent, toxicity being the main reason for it. The significantly greater persistence of some combinations may be useful for making decisions when initiating cART.

References

Palella

F.J.

Jr. , Delaney

K.M.

, Moorman

A.C.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–860.

Jaggy

, von Overbeck

, Ledergerber

Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: 877–878.

Thompson

M.A.

, Aberg

J.A.

, Cahn

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321–333.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 10 January 2011. Accessed 19 December 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Panel de expertos de GESIDA y Plan Nacional sobre el Sida. [National Consensus Document by GESIDA/National AIDS Plan on Antiretroviral Treatment in Adults Infected by the Human Immunodeficiency Virus]. Spanish. (Updated January 2011. Accesssed 19 December 2011.) Available from http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2011-Documentoconsenso-TAR-adulto-verordenador.pdf.

Sobrino-Vegas

, García-San Miguel

, Caro-Murillo

A.M.

Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res 2009; 7: 224–230.

Sobrino-Vegas

, Rodríguez-Urrego

, Berenguer

Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care. Antivir Ther 2012; 17: 1–8.

Palella

F.J.

Jr. , Chmiel

J.S.

, Moorman

A.C.

, Holmberg

S.D.

Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16: 1617–1626.

Cicconi

, Cozzi-Lepri

, Castagna

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort ofantiretroviral-naive patients. HIV Med 2010; 11: 104–113.

10.

T.T.

, Ledergerber

, Keiser

Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197: 1685–1694.

11.

Sabundayo

B.P.

, McArthur

J.H.

, Langan

, Gallan

J.E.

, Margolick

J.B.

High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. Pharmacotherapy 2006; 26: 674–681.

12.

Yuan

, L'Italien

, Mukherjee

, Iloeje

U.H.

Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006; 7: 156–162.

13.

Palacio

, Li

, Wilson

T.E.

Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivety. AIDS 2004; 18: 621–630.

14.

Cramer

J.A.

, Roy

, Burneti

Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44–47.

15.

Bae

J.W.

, Guyer

, Grimm

, Altice

F.L.

Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011; 25: 279–290.

16.

Willig

J.H.

, Abroms

, Westfall

A.O.

Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22: 1951–1960.

17.

Sobrino-Vegas

, Gutierrez

, Berenguer

The cohort of the Spanish HIV research network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up. Enferm Infecc Microbiol Clin 2011; 29: 645–653.

18.

Prentice

R.L.

, Kalbfleisch

J.D.

, Peterson

A.V.

Jr. , Flournoy

, Farewell

V.T.

, Breslow

N.E.

The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541–554.

19.

Putter

, Fiocco

, Geskus

R.B.

Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389–2430.

20.

Geskus

R.B.

Cause-specific cumulative incidence estimation and the Fine and Gray model under both left truncation and right censoring. Biometrics 2011; 67: 39–49.

21.

Fine

J.P.

, Gray

R.J.

A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

22.

Lau

, Cole

S.R.

, Gange

S.J.

Competing risk regression models for epidemiologic data. Am J Epidemiol 2009; 170: 244–256.

23.

Mocroft

, Youle

, Moore

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15: 185–194.

24.

d'Arminio Monforte

, Cozzi Lepri

, Rezza

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14: 499–507.

25.

Elzi

, Marzolini

, Furrer

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170: 57–65.

26.

Juday

, Grimm

, Zoe-Powers

, Willig

, Kim

A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care 2011; 23: 1154–1162.

27.

Maggiolo

, Leone

, Cologni

, Valenti

, Quinzan

, Suter

Persistence on first line HAART is influenced by dosing schedule. XVIII International AIDS Conference. 18–23 July 2010, Vienna, Austria. Abstract 178.

28.

Maggiolo

, Arici

, Airoldi

Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. J Antimicrob Chemother 2007; 59: 569–572.

29.

Bongiovanni

, Cicconi

, Landonio

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents 2005; 26: 88–91.

30.

Reekie

, Reiss

, Ledergerber

A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Med 2011; 12: 259–268.

31.

Smith

C.J.

, Olsen

C.H.

, Mocroft

The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS 2008; 22: 47–56.

32.

Lichtenstein

K.A.

, Delaney

K.M.

, Armon

Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32: 48–56.

33.

Curkendall

S.M.

, Richardson

J.T.

, Emons

M.F.

, Fisher

A.E.

, Everhard

Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2007; 8: 483–490.

34.

Kelleher

, Cross

, Dunkle

Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. Clin Ther 1999; 21: 1182–1192.

35.

, Yang

, Thiry

Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated with atazanavir/r and lopinavir/r in the CASTLE study. J Int AIDS Soc 2008; 11: 8.

Persistence of Novel First-Line Antiretroviral Regimes in a Cohort of HIV-Positive Subjects,Coris 2008–2010

Abstract

Background

Methods

Results

Conclusions

References